- Home
- ALNY vs PEG Comparison
ALNY vs PEG Comparison
Compare ALNY & PEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALNY | PEG |
|---|---|---|
| Founded | 2002 | 1903 |
| Country | United States | United States |
| Employees | 115 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Power Generation |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.9B | 39.6B |
| IPO Year | 2004 | 1994 |
Fundamental Metrics
Financial Performance| Metric | ALNY | PEG |
|---|---|---|
| Price | $267.31 | $79.75 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 28 | 12 |
| Target Price | ★ $471.00 | $92.79 |
| AVG Volume (30 Days) | 1.5M | ★ 2.4M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 3.37% |
| EPS Growth | ★ 206.88 | 19.21 |
| EPS | ★ 2.33 | 1.48 |
| Revenue | $1,037,418,000.00 | ★ $12,168,000,000.00 |
| Revenue This Year | $52.67 | $4.89 |
| Revenue Next Year | $31.48 | $4.16 |
| P/E Ratio | $114.59 | ★ $53.77 |
| Revenue Growth | ★ 22.88 | 18.25 |
| 52 Week Low | $264.21 | $76.05 |
| 52 Week High | $495.55 | $91.26 |
Technical Indicators
Market Signals| Indicator | ALNY | PEG |
|---|---|---|
| Relative Strength Index (RSI) | 33.69 | 46.59 |
| Support Level | N/A | $77.27 |
| Resistance Level | $318.35 | $81.50 |
| Average True Range (ATR) | 15.80 | 1.40 |
| MACD | -3.99 | -0.28 |
| Stochastic Oscillator | 0.35 | 40.39 |
Price Performance
Historical ComparisonAbout ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
About PEG Public Service Enterprise Group Incorporated
Public Service Enterprise Group is the holding company for a regulated utility (PSE&G) and PSEG Power, which owns all or a share of three nuclear plants and clean energy projects. PSE&G provides regulated gas and electricity delivery services in New Jersey to a combined 4.3 million customers. Public Service Enterprise Group also operates the Long Island Power Authority system under a contract extension through 2030. In 2022, the company sold its gas and oil power plants in the mid-Atlantic, New York, and the Northeast.